Get started
Author

Ralf Stemkens

Observed names: R Stemkens, R. Stemkens, Stemkens, R
ORCID: 0009-0008-6912-4163
Observed ORCID: 0009-0008-6912-4163
OpenAlex ID: A5030595352
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment
2023 · Sanne M.H. Zweijpfenning, Rob Aarnoutse, et al. · CHEST Journal · 40
PDF
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30
PDF
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
2023 · Ralf Stemkens, Veronique de Jager, et al. · Antimicrobial Agents and Chemotherapy · 18
PDF
Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
2024 · Sandra Salillas, Jelmer Raaijmakers, et al. · Antimicrobial Agents and Chemotherapy · 17
A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
2024 · Ralf Stemkens, Arthur Lemson, et al. · Journal of Antimicrobial Chemotherapy · 16
PDF
How to use quality indicators for antimicrobial stewardship in your hospital: a practical example on outpatient parenteral antimicrobial therapy
2022 · Ralf Stemkens, Jeroen A. Schouten, et al. · Clinical Microbiology and Infection · 14
PDF
Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment
2019 · R. Stemkens, C.H.C. Litjens, et al. · International Journal of Antimicrobial Agents · 13
PDF
Treatment of nontuberculous mycobacterial pulmonary disease requires a stepwise and multidisciplinary approach
2025 · Arthur Lemson, Arjan van Laarhoven, et al. · Expert Review of Respiratory Medicine · 10
Successful addition of topical antibiotic treatment after surgery in treatment-refractory nontuberculous mycobacterial skin and soft tissue infections
2023 · Ralf Stemkens, Maarten Cobussen, et al. · Antimicrobial Agents and Chemotherapy · 10
PDF
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5
PDF
Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system
2025 · J. Raaijmakers, S. Salillas, et al. · Antimicrobial Agents and Chemotherapy · 4
Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations
2024 · Ralf Stemkens, Chaima Mouhdad, et al. · Journal of Antimicrobial Chemotherapy · 4
PDF
Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease
2024 · A. Lemson, T.A. Koster, et al. · IJTLD OPEN · 2
Medication adherence in patients with nontuberculous mycobacterial disease
2025 · Arthur Lemson, Fleur Dijkhuizen, et al. · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · 1
Pharmacokinetics of minocycline with and without rifampicin co-administration in patients with nontuberculous mycobacterial disease
2026 · Arthur Lemson, Rob Aarnoutse, et al. · Journal of Antimicrobial Chemotherapy
Acetylator status-guided rapid reintroduction of isoniazid in tuberculosis patients with drug-induced hepatotoxicity
2026 · Cynthia van Arkel, Ralf Stemkens, et al. · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Exposure to azithromycin and the effect of co-administration of rifampicin in patients with non-tuberculous mycobacterial disease
2026 · M P Rodgers, R Stemkens, et al. · Journal of Antimicrobial Chemotherapy
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
2025 · Jelmer Raaijmakers, Rob Aarnoutse, et al. · Journal of Antimicrobial Chemotherapy
PDF
Rifampicin leads to subtherapeutic azithromycin exposures in NTM disease treatment
2025 · Michael Rodgers, Victor Dahl, et al.
Phenotyping with single-dose isoniazid to identify slow acetylators in patients with drug-induced hepatotoxicity
2025 · Cynthia van Arkel, Ralf Stemkens, et al.
Towards utilizing the full potential of old – but not outdated – drugs for tuberculosis and nontuberculous mycobacterial disease: A clinical pharmacological perspective
2025 · Ralf Stemkens · Radboud University Press eBooks
PDF
Bedaquiline does not enhance clofazimine treatment efficacy with an azithromycin-ethambutol backbone against Mycobacterium avium in a hollow fibre system
2024 · Jelmer Raaijmakers, Sandra Salillas, et al. · Journal of Global Antimicrobial Resistance
Inhaled clofazimine adminsitration increases antimycobacterial effect compared to oral administration in a hollow-fibre system
2024 · Jelmer Raaijmakers, Rob E. Aarnoutse, et al. · Journal of Global Antimicrobial Resistance
Works count: 24
Citation count: 184
H-index: 9
I10-index: 9
Year
Topic
Type